PMLT21063 / APEC1621N / Mullen
Basic Study Information
Purpose:
This phase II pediatric MATCH treatment trial studies how well selpercatinib works
in treating patients with solid tumors that may have spread from where they first
started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas,
or histiocytic disorders that have activating RET gene alterations. Selpercatinib
may block the growth of cancer cells that have specific genetic changes in an important
signaling pathway (called the RET pathway) and may reduce tumor size.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Craig Mullen
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search